{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:06:00Z","timestamp":1790039160738,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T00:00:00Z","timestamp":1463788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,21]],"date-time":"2016-05-21T00:00:00Z","timestamp":1463788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI081062"],"award-info":[{"award-number":["R01AI081062"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Semant"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuropathy often occurs following drug treatment such as chemotherapy. Severe instances of neuropathy can result in cessation of life-saving chemotherapy treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>To support data representation and analysis of drug-associated neuropathy adverse events (AEs), we developed the Ontology of Drug Neuropathy Adverse Events (ODNAE). ODNAE extends the Ontology of Adverse Events (OAE). Our combinatorial approach identified 215 US FDA-licensed small molecule drugs that induce signs and symptoms of various types of neuropathy. ODNAE imports related drugs from the Drug Ontology (DrON) with their chemical ingredients defined in ChEBI. ODNAE includes 139 drug mechanisms of action from NDF-RT and 186 biological processes represented in the Gene Ontology (GO). In total ODNAE contains 1579 terms. Our analysis of the ODNAE knowledge base shows neuropathy-inducing drugs classified under specific molecular entity groups, especially carbon, pnictogen, chalcogen, and heterocyclic compounds. The carbon drug group includes 127 organic chemical drugs. Thirty nine receptor agonist and antagonist terms were identified, including 4 pairs (31 drugs) of agonists and antagonists that share targets (e.g., adrenergic receptor, dopamine, serotonin, and sex hormone receptor). Many drugs regulate neurological system processes (e.g., negative regulation of dopamine or serotonin uptake). SPARQL scripts were used to query the ODNAE ontology knowledge base.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>ODNAE is an effective platform for building a drug-induced neuropathy knowledge base and for analyzing the underlying mechanisms of drug-induced neuropathy. The ODNAE-based methods used in this study can also be extended to the representation and study of other categories of adverse events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13326-016-0069-x","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:08:05Z","timestamp":1463962085000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Ontology-based collection, representation and analysis of drug-associated neuropathy adverse events"],"prefix":"10.1186","volume":"7","author":[{"given":"Abra","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Racz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguk","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoshuang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Rinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,21]]},"reference":[{"key":"69_CR1","doi-asserted-by":"crossref","unstructured":"Delforge M, Blade J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010;11(11):1086\u201395.","DOI":"10.1016\/S1470-2045(10)70068-1"},{"issue":"1","key":"69_CR2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11910-003-0043-8","volume":"3","author":"LH Weimer","year":"2003","unstructured":"Weimer LH. Medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2003;3(1):86\u201392.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"69_CR3","doi-asserted-by":"crossref","unstructured":"He Y, Sarntivijai S, Lin Y, Xiang Z, Guo A, Zhang S, et al. OAE: The Ontology of Adverse Events. J Biomed Semant. 2014;5:29.","DOI":"10.1186\/2041-1480-5-29"},{"key":"69_CR4","doi-asserted-by":"crossref","unstructured":"Sarntivijai S, Zhang S, Jagannathan DG, Zaman S, Burkhart KK, Omenn GS, He Y, Athey BD, Abernethy DR: Linking MedDRA-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors. Drug safety 2016 [Epub ahead of print]","DOI":"10.1007\/s40264-016-0414-0"},{"key":"69_CR5","doi-asserted-by":"publisher","unstructured":"He Y: Ontology-based vaccine and drug adverse event representation and theory-guided systematic causal network analysis toward integrative pharmacovigilance research. Current Pharmacology Reports 2016, In press (DOI: 10.1007\/s40495-016-0055-0):1-16.","DOI":"10.1007\/s40495-016-0055-0):1-16"},{"issue":"1","key":"69_CR6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/2041-1480-4-44","volume":"4","author":"J Hanna","year":"2013","unstructured":"Hanna J, Joseph E, Brochhausen M, Hogan WR. Building a drug ontology based on RxNorm and other sources. J Biomed Semant. 2013;4(1):44.","journal-title":"J Biomed Semant"},{"issue":"4","key":"69_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/amiajnl-2011-000116","volume":"18","author":"SJ Nelson","year":"2011","unstructured":"Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc. 2011;18(4):441\u20138.","journal-title":"J Am Med Inform Assoc"},{"key":"69_CR8","doi-asserted-by":"crossref","unstructured":"Hastings J, de Matos P, Dekker A, Ennis M, Harsha B, Kale N, et al. The ChEBI reference database and ontology for biologically relevant chemistry: enhancements for 2013. Nucleic Acids Res. 2013;41(Database issue):D456\u201363.","DOI":"10.1093\/nar\/gks1146"},{"key":"69_CR9","doi-asserted-by":"crossref","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25\u20139.","DOI":"10.1038\/75556"},{"key":"69_CR10","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1038\/psp.2014.11","volume":"3","author":"J Hur","year":"2014","unstructured":"Hur J, Guo AY, Loh WY, Feldman EL, Bai JP. Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy. CPT Pharmacometrics Syst Pharmacol. 2014;3:e114.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"69_CR11","unstructured":"The Common Terminology Criteria for Adverse Events (CTCAE) [http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html, access on 7 Oct 2015]"},{"issue":"2","key":"69_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"key":"69_CR13","first-page":"100","volume":"2013","author":"G Jiang","year":"2013","unstructured":"Jiang G, Liu H, Solbrig HR, Chute CG. ADEpedia 2.0: Integration of Normalized Adverse Drug Events (ADEs) Knowledge from the UMLS. AMIA Jt Summits Transl Sci Proc. 2013;2013:100\u20134.","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"key":"69_CR14","unstructured":"Brown SH, Elkin PL, Bauer BA, Wahner-Roedler D, Husser CS, Temesgen Z, Hardenbrook SP, Fielstein EM, Rosenbloom ST: SNOMED CT: utility for a general medical evaluation template. AMIA Annual Symposium proceedings\/AMIA Symposium AMIA Symposium 2006:101-105"},{"key":"69_CR15","first-page":"64","volume":"2013","author":"O Hassanzadeh","year":"2013","unstructured":"Hassanzadeh O, Zhu Q, Freimuth R, Boyce R. Extending the \u201cweb of drug identity\u201d with knowledge extracted from United States product labels. AMIA Jt Summits Transl Sci Proc. 2013;2013:64\u20138.","journal-title":"AMIA Jt Summits Transl Sci Proc"},{"key":"69_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1756-0500-3-175","volume":"3","author":"Z Xiang","year":"2010","unstructured":"Xiang Z, Courtot M, Brinkman RR, Ruttenberg A, He Y. OntoFox: web-based support for ontology reuse. BMC Res Notes. 2010;3:175. 1-12.","journal-title":"BMC Res Notes"},{"issue":"1","key":"69_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2041-1480-6-4","volume":"6","author":"Z Xiang","year":"2015","unstructured":"Xiang Z, Zheng J, Lin Y, He Y. Ontorat: Automatic generation of new ontology terms, an-notations, and axioms based on ontology design patterns. J Biomed Semant. 2015;6(1):4 (10 pages).","journal-title":"J Biomed Semant"},{"key":"69_CR18","first-page":"279","volume-title":"The 2nd International Conference on Biomedical Ontologies (ICBO): 2011","author":"Z Xiang","year":"2013","unstructured":"Xiang Z, Mungall C, Ruttenberg A, He Y. Ontobee: A linked data server and browser for ontology terms. In: The 2nd International Conference on Biomedical Ontologies (ICBO): 2011. Buffalo: CEUR Workshop Proceedings; 2013. p. 279\u201381."},{"key":"69_CR19","unstructured":"FDA Adverse Event Reporting System (FAERS) [FDA Adverse Event Reporting System (FAERS): http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm, accessed on 22 May 2015.]"},{"key":"69_CR20","first-page":"89","volume-title":"IFOMIS reports","author":"P Grenon","year":"2003","unstructured":"Grenon P. Spatio-temporality in Basic Formal Ontology. In: Grenon P, editor. IFOMIS reports. Leipzig: Institute for Formal Ontology and Medical Information Science at the Faculty of Medicine of the University of Leipzig; 2003. p. 89."},{"issue":"1","key":"69_CR21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1207\/s15427633scc0401_5","volume":"4","author":"P Grenon","year":"2004","unstructured":"Grenon P, Smith B. SNAP and SPAN: Towards Dynamic Spatial Ontology. Spat Cogn Comput. 2004;4(1):69\u2013103.","journal-title":"Spat Cogn Comput"},{"key":"69_CR22","doi-asserted-by":"crossref","unstructured":"Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol. 2007;25(11):1251\u20135.","DOI":"10.1038\/nbt1346"},{"issue":"1","key":"69_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.phrs.2008.10.005","volume":"59","author":"A Bertolini","year":"2009","unstructured":"Bertolini A, Tacchi R, Vergoni AV. Brain effects of melanocortins. Pharmacol Res. 2009;59(1):13\u201347.","journal-title":"Pharmacol Res"},{"issue":"4","key":"69_CR24","first-page":"254","volume":"13","author":"N Olney","year":"2010","unstructured":"Olney N, Rosen H. AVP-923, a combination of dextromethorphan hydrobromide and quinidine sulfate for the treatment of pseudobulbar affect and neuropathic pain. IDrugs. 2010;13(4):254\u201365.","journal-title":"IDrugs"},{"issue":"3","key":"69_CR25","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00401-006-0106-4","volume":"112","author":"DD Tshala-Katumbay","year":"2006","unstructured":"Tshala-Katumbay DD, Palmer VS, Lasarev MR, Kayton RJ, Sabri MI, Spencer PS. Monocyclic and dicyclic hydrocarbons: structural requirements for proximal giant axonopathy. Acta Neuropathol. 2006;112(3):317\u201324.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"69_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/15287390600751173","volume":"70","author":"KD Thrall","year":"2007","unstructured":"Thrall KD, Gies RA, Cartmell AM, Wu H, Soelberg JJ, Klein JA. A liquid chromatographic-mass spectrometric method to evaluate the distribution kinetics of 1,2-diethylbenzene and its metabolite 1,2-diacetylbenzene in the F344 male rat. J Toxic Environ Health A. 2007;70(1):67\u201372.","journal-title":"J Toxic Environ Health A"},{"issue":"2","key":"69_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/jat.2550130209","volume":"13","author":"F Gagnaire","year":"1993","unstructured":"Gagnaire F, Marignac B, de Ceaurriz J. Triethylbenzene-induced sensorimotor neuropathy in rats. J Appl Toxicol. 1993;13(2):123\u20138.","journal-title":"J Appl Toxicol"},{"key":"69_CR28","doi-asserted-by":"crossref","unstructured":"Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, et al. Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib. Bioorg Med Chem. 2010;18(19):6977\u201386.","DOI":"10.1016\/j.bmc.2010.08.026"},{"key":"69_CR29","doi-asserted-by":"crossref","unstructured":"Low Y, Sedykh A, Fourches D, Golbraikh A, Whelan M, Rusyn I, et al. Integrative chemical-biological read-across approach for chemical hazard classification. Chem Res Toxicol. 2013;26(8):1199\u2013208.","DOI":"10.1021\/tx400110f"},{"issue":"4","key":"69_CR30","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/bioinformatics\/btu692","volume":"31","author":"A Roy","year":"2015","unstructured":"Roy A, Skolnick J. LIGSIFT: an open-source tool for ligand structural alignment and virtual screening. Bioinformatics. 2015;31(4):539\u201344.","journal-title":"Bioinformatics"},{"issue":"Web Server issu","key":"69_CR31","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gkr320","volume":"39","author":"TW Backman","year":"2011","unstructured":"Backman TW, Cao Y, Girke T. ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res. 2011;39(Web Server issue):W486\u201391.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"69_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1586\/14760584.2014.923762","volume":"13","author":"Y He","year":"2014","unstructured":"He Y. Ontology-supported research on vaccine efficacy, safety and integrative biological networks. Expert Rev Vaccines. 2014;13(7):825\u201341.","journal-title":"Expert Rev Vaccines"}],"container-title":["Journal of Biomedical Semantics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13326-016-0069-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13326-016-0069-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13326-016-0069-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13326-016-0069-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:27:46Z","timestamp":1790036866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13326-016-0069-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["69"],"URL":"https:\/\/doi.org\/10.1186\/s13326-016-0069-x","relation":{},"ISSN":["2041-1480"],"issn-type":[{"value":"2041-1480","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,21]]},"assertion":[{"value":"5 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"29"}}